Skip to main content

Table 3 Ofatumumab in clinical trials

From: Novel agents for chronic lymphocytic leukemia

Study agents

Other agents

Disease

Dosage

Clinical trials

No. of Pts

Response

Reference

Ofatumumab

 

Untreated

2000/1000 mg

Phase II

77

CR:5/4%

[28]

      

ORR:55/36%

 

Ofatumumab

Lenalidomide

Relapsed

1000 mg

Phase II

36

CR:24%

[31]

      

ORR:68%

 

Ofatumumab

Lenalidomide

Relapsed

2000 mg

Phase II

17

ORR:43%

[32]

  

Refractory

   

SD:21%

 
  1. Abbreviations: ORR overall response rate, CR complete remission, SD stable disease.